---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-241849"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2023-09-26T23:59:59+00:00"
generated_at: "2026-06-10T08:45:21.473113+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics reports positive Phase 2a INTEGRIS-PSC data for bexotegrast in PSC

## Summary
- Trial met primary safety endpoint; bexotegrast well tolerated with 94% completing 12 weeks, no drug-related SAEs.
- Exploratory efficacy: significant reduction in ELF score and PRO-C3 at 160 mg vs placebo at Week 12.
- Dose-dependent trend in ALP reduction; MRI imaging suggests improved hepatocyte function and bile flow.
- High-dose 320 mg interim data expected Q1 2024; full 24-week data mid-2024.
- Company to host webcast today at 8:00 AM ET to discuss results.

## SEC filing metadata
- accession: 0001193125-23-241849
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2023-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000119312523241849/0001193125-23-241849-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000119312523241849/d473253d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-241849
- JSON: https://secwatch.observer/filing/0001193125-23-241849.json
- Plain text: https://secwatch.observer/filing/0001193125-23-241849.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.